Tag Archives: Deals

Pharm Exec’s Pharma Top 50 in Brief

The vigorous return of M&A activity this year brings us back to the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system? Anecdotal evidence combined with some discomfiting statistics on pipeline productivity of the past 15 years suggests that the answer […]
Posted in Deals, Strategy | Also tagged , , , | Leave a comment

Pharma Leads the Way in M&A

 The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal. The sector’s deals have been valued at US$252.5 bn,  a 16.9% market share in global M&A. Deal value is 48.2% above the whole of 2013’s value, and four deals account for a 61.3% share in the […]
Posted in Deals, Europe, Global | Also tagged | Leave a comment

Big Biotech Gains Offset Big Pharma Losses

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
Posted in Biotech, Deals, Global, Strategy | Also tagged , , , , | Leave a comment

The Urge to Merge: Dealmaking Lessons from Pharma History

By Cliff Kalb. The major pressures hindering pharmaceutical industry success have not changed—payer constraints on drug costs, R&D productivity, an increasingly risk-averse regulatory climate, generic encroachment, and negative public perceptions linked to reputation. Looking at the latest rendition of the Pharma 50, prescription drug revenue rankings for the top 10 major global players in 2013 […]
Posted in Deals, Global, Op-Ed, Strategy | Also tagged , , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Posted in Biotech, Deals, Global, healthcare | Also tagged , , , , | Leave a comment
  • Categories

  • Meta